Effect of silymarin administration on TNF-α serum concentration in peritoneal dialysis patients

Phytotherapy Research

Volumn 24, Issue 11, 2010, Pages 1654-1657

  Nazemian, Fatemeh ^a   Karimi, Gholamreza ^a,b   Moatamedi, Mahdi ^c   Charkazi, Somayeh ^c   Shamsara, Jamal ^c   Mohammadpour, Amir Hooshang ^b,c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Peritoneal dialysis; Silymarin; TNF

Indexed keywords

ALBUMIN; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 1BETA; SILYMARIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL CRAMP; ADULT; ANAPHYLAXIS; ANEMIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NAUSEA; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

EID: 78049435070     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3175     Document Type: Article

References (17)

1. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. 2003. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 14: 1776-1784.
2. Gazak R, Walterova D, Kren V. 2007. Silybin and silymarin - new and emerging applications in medicine. Curr Med Chem 14: 315-338.
3. Hayat A, Kamili MA, Samia R et al. 2007. Peritoneal dialysis for adults with acute renal failure: an underutilized modality. Saudi J Kidney Dis Transpl 18: 195-199.
4. Jofre R, Rodriguez-Benitez P, Lopez-Gomez JM, Perez-Garcia R. 2006. Inflammatory syndrome in patients on haemodialysis. J Am Soc Nephrol 17: S274-S280.
5. Kang JS, Park SK, Yang KH, Kim HM. 2003. Silymarin inhibits TNF-alpha-induced expression of adhesion molecules in human umbilical vein endothelial cells. FEBS Lett 550: 89-93.
6. Kim JK, Park BS, Park MJ et al. 2001. The predictive parameters of erythropoietin hyporesponsiveness in patients on continuous ambulatory peritoneal dialysis. Korean J Intern Med 16: 110-117.
7. Kren V, Walterova D. 2005. Silybin and silymarin - new effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149: 29-41.
8. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. 1999. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol 163: 6800-6809.
9. Min K, Yoon WK, Kim SK, Kim BH. 2007. Immunosuppressive effect of silibinin in experimental autoimmune encephalomyelitis. Arch Pharm Res 30: 1265-1272.
10. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimburger O, Lindholm B. 2004. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 24: 327-339.
11. Pradhan SC, Girish C. 2006. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 124: 491-504.
12. Ryckelynck JP, Lobbedez T, Pujo M, El Haggan W, Hurault De Ligny B. 2003. [Inflammation in peritoneal dialysis]. Nephrologie 24: 367-370.
13. Saller R, Melzer J, Reichling J, Brignoli R, Meier R. 2007. An updated systematic review of the pharmacology of silymarin. Forsch Komplementmed 14: 70-80.
14. Stenvinkel P, Chung SH, Heimburger O, Lindholm B. 2001. Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Perit Dial Int 21 (Suppl): S157-S162.
15. Wang AY-M. 2007. Cardiovascular risk factors in peritoneal dialysis patients revisited. Perit Dial Int 27: S223-S227.
16. Wei M, Bargman JM, Oreopoulos DG. 2007. Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis. Int Urol Nephrol 39: 935-940.
17. Zi X, Mukhtar H, Agarwal R. 1997. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha. Biochem Biophys Res Commun 239: 334-339.